#估值

Games Workshop: An Exceptional Warhammer Compounder, Priced for Continued Excellence

Games Workshop is the vertically integrated owner of the Warhammer universe, designing, manufacturing and selling miniatures, paints, books and licensed media from a single UK creative stack at returns on capital few public companies reach. FY2025 delivered £617.5m of total revenue and £262.8m of profit before tax, and FY2026 is guided higher even as the volatile licensing line steps down from £52.5m to at least £30m. Rating Hold: an exceptional IP compounder whose roughly 35x earnings multiple already prepays years of flawless execution, leaving no margin of safety at £217.

Simulations Plus: A Credible Drug-Modeling Specialist, Now Priced as a Near-Cash Deal Stock

Simulations Plus builds scientifically trusted drug-development modeling software (GastroPlus, MonolixSuite, ADMET Predictor, DILIsym), but its revenue mix has drifted toward lower-margin services since the 2024 Pro-ficiency acquisition, which pulled FY2025 gross margin to 58% and triggered a $77.2m impairment. On 2026-06-26 the equity trades as a near-cash event security: Altaris' agreed $18.50-per-share takeout caps upside just above the $18.14 close, while a broken deal would reopen real downside. Rating Avoid: a thin-spread cash-deal security whose unresolved software-mix question still sits underneath the transaction.

Carl Zeiss Meditec: A High-Grade Ophthalmology Franchise Forced to Relearn Its Operating Model in China

Carl Zeiss Meditec is a premium German ophthalmology and microsurgery franchise where ophthalmology drives about 77% of sales and recurring revenue has climbed from 9% two decades ago to roughly 50%. A simultaneous China VBP shock and weak Americas equipment demand crushed H1 FY2025/26 adjusted EBITA margin to 6.1% from 10.7%, and the shares have fallen more than 80% from their 2021 peak to 27.96 euros. Rating Watch: a high-quality medtech franchise in a real trough, but the China relisting and margin-restoration bridge is still too unproven for a clean entry, with the ideal buy zone at 24 to 26 euros.

SAP: A High-Quality Incumbent Late in Its Cloud Migration, Now Priced for Proof Rather Than Possibility

SAP is the incumbent enterprise-applications vendor migrating its captive ERP installed base from license-and-support to cloud subscriptions, where process centrality keeps converting into long-duration economics. In 2025 cloud revenue reached 21.0 billion euros and predictable revenue 86%, with total cloud backlog of 77.3 billion euros, yet FY2026 guidance for slightly decelerating current-backlog growth reset the stock more than 50% below its early-2025 peak to about 21.5x earnings. Rating Hold: the cloud transition is genuinely working and the franchise is high quality, but at today's price the market already asks for proof rather than possibility, with the ideal buy zone at 95 to 101 euros.

Shimano: A Fortress Cycling Franchise in a Real Trough, But the Price Already Pays for the Repair

Shimano is a century-old Japanese precision manufacturer whose bicycle drivetrain and braking franchise still drives roughly three-quarters of group sales, with fishing tackle the resilient second engine. Group operating income has fallen from a 169.2 billion yen pandemic peak in 2022 to a guided 47.0 billion yen in 2026 (margin near 10% against a historical 20% to 25%), and at 17,340 yen (about 35x guided earnings) the price already discounts much of the eventual repair, leaving no margin of safety. Rating Hold: a fortress-quality franchise in a real but uncertain trough, where the moat is intact yet the entry price is not yet compelling, with the ideal buy zone at 12,000 to 14,000 yen.

Hengrui Pharmaceuticals: A Fortress Innovation Platform, But RMB 50 Already Pays for the Upgrade

Hengrui Pharmaceuticals is China's largest listed innovative-drug platform, still earning mainly from domestic drug sales while its valuation increasingly rests on converting self-funded R&D into commercial franchises and recurring overseas licensing income. 2025 revenue reached RMB 31.63 billion with net profit of RMB 7.71 billion and a fortress balance sheet holding RMB 40.16 billion of cash, yet at RMB 50.04 (about 41x trailing earnings) the price sits above the conservative fair value and leaves no margin of safety. Rating Hold: a rare high-quality China pharma platform already priced for an innovation-monetization upgrade it has not yet fully earned.

Pan American Silver: Juanicipio Upgrades the Silver Book, But $44 Already Pays for the Transition

Pan American Silver is an Americas-focused, silver-first precious-metals miner whose September 2025 MAG acquisition added a 44% stake in the high-grade Juanicipio mine, lifting 2026 guidance to 25-27 Moz silver and 700-750 koz gold on a net-cash balance sheet. The portfolio is genuinely better than the 2022 trough, but at $44.39 the stock trades near 9.2x EV/EBITDA on a 7% free-cash-flow yield, already pricing the upgrade while Escobal and Navidad stay politically frozen and 2026 cost guidance leans on $70 silver against roughly $58 spot. Rating Hold: a better silver miner with no clear margin of safety, where a buy needs either the mid-$20s or proof that normalized free cash flow holds closer to the base case than the conservative one.

RemeGen: Two Self-Developed Drug Franchises and an Export Licensing Engine, With the A-Share Already Pricing a Cleaner Future Than the Filings Justify

RemeGen is a commercializing China innovative-biopharma with two self-developed franchises — telitacicept in autoimmune disease and disitamab vedotin in ADC oncology — plus an ex-China licensing engine (Vor Bio, Santen, AbbVie) that has become part of the business model. 2025 product sales reached CNY 2.31bn (up 35.8%) and reported profit turned positive at CNY 709.7m, but operating cash flow was only CNY 52.3m (about 0.07x conversion), Q1 2026 profit after non-recurring items stayed negative, and the A-share trades at roughly a 96.5% premium to the H-share — above even the optimistic per-share value. Rating Avoid: a good company at the wrong price on the Shanghai line, where an entry needs both a lower A-share price (CNY 36-40) and proof that recurring earnings quality has caught up to the approvals.

Zhejiang Shuanghuan Driveline: A Precision-Gear Cash Engine Carrying a Still-Optional Robot-Reducer Bet

Zhejiang Shuanghuan Driveline is a precision-gear specialist whose profit still comes from automotive transmission and e-drive gears, with robot RV reducers (housed in 61.29%-owned Huandong, now seeking a STAR Market listing) as a still-speculative second engine. Four straight years of rising revenue (CNY 9.11bn in 2025) and attributable profit (CNY 1.262bn), with operating cash flow above net income every year, make the transition credible, yet Q1 2026 recurring profit fell 4.04% and the loudest humanoid-customer claims stay unverified in primary filings. Rating Hold: the auto-gear cash engine is real and the reducer option is credible, but at CNY 39.42 the price already capitalizes much of that optionality, leaving no obvious margin of safety.

Kelun-Biotech: A Commercializing China ADC Franchise Priced for Much of Its sac-TMT and MSD Global Success

Kelun-Biotech is a commercial-stage China ADC developer whose equity value is dominated by its sac-TMT (TROP2) franchise in Greater China plus ex-China royalty economics from MSD. In 2025 product sales inflected to RMB542.7m within RMB2.06bn total revenue and the balance sheet held RMB4.56bn cash with no borrowings, yet the company still posted a RMB382.0m net loss as nearly all equity value concentrates in one molecule. Rating Hold: a real ADC franchise is forming, but at HK$419 the stock already prices in much of the sac-TMT China plus MSD global success path and offers no margin of safety.

Gold Fields: A De-Rated but Reshaped Global Gold Miner Still Priced for Execution and Country Risk

Gold Fields is a globally diversified gold miner running eight operating mines across South Africa, Ghana, Chile, Peru and Australia plus the Windfall project in Canada, reshaped around the new Salares Norte flagship and the Osisko and Gold Road acquisitions. 2025 delivered a realized gold price of US$3,496/oz, production of 2.438Moz and adjusted free cash flow of US$2.97 billion, yet the US ADR has de-rated quickly from US$38.60 to US$31.88 in a broad gold selloff rather than on any company-specific break. Rating Cautious Buy: an improved but still-cyclical portfolio trading at a discount to peers, where Salares Norte execution and Ghana Tarkwa fiscal terms keep a full-quality rerating away and the ideal buy sits at US$26 to US$29, below the current price.

AngloGold Ashanti: A Re-Rated Major Gold Miner in Transition, Cash-Rich but Reserve-Light and Priced Near Fair Value

AngloGold Ashanti is a globally diversified major gold miner producing 3.1Moz a year across roughly ten mines, reshaped by the 2024 Centamin/Sukari acquisition and a 2023 redomicile to a UK plc with a primary NYSE listing. 2025 delivered record free cash flow of US$2.9 billion and a year-end adjusted net cash position, but the shares have already re-rated about 69% in a year and a 21.91Moz reserve base implies only about seven years of reserve life against 3.1Moz of annual output. Rating Hold: a much-improved cyclical cash generator now trading near fair value at roughly 0.85x P/NAV, where the easy rerating money has been made and further upside hinges on reserve replacement (Nevada's Arthur) and a gold tape staying generous.

Barrick Mining: A World-Class Gold-and-Copper Portfolio in Transition, Discounted for Complexity and Priced Near Fair Value

Barrick Mining is a senior gold-and-copper miner with world-class reserve depth (85Moz gold, 18Mt copper), district quality in Nevada and Pueblo Viejo, and a balance sheet strong enough to fund both record shareholder returns and future growth. Record 2025 cash flow (US$7.69 billion operating, US$3.87 billion free) proved the operating leverage, but the stock trades at a persistent discount to peers because sovereign risk in Mali, a Reko Diq budget review, a Newmont dispute over Nevada, and an unfinished North American carve-out all cloud the path from ore to shareholder value. Rating Hold: the gold cash flows and copper optionality are real, but the price already reflects strong metals and leaves only a moderate cushion against execution risk, with a defensible entry only below roughly US$26.

OR Royalties: A Mid-Tier Royalty Franchise Re-Rating With Visible Growth, Priced Around Fair Value

OR Royalties is a mid-tier precious-metals royalty and streaming company anchored by a 3-5% NSR on the Tier-1 Canadian Malartic mine, with 196 interests and 23 producing assets. 2025 revenue jumped 45% to US$277.4 million on a soaring realized gold price and the company finished the year debt-free, while the 2030 outlook of 120,000-135,000 GEOs is backed by named projects rather than blue-sky exploration; yet much of the earnings step-up is gold-price torque and Canadian Malartic still dominates the story. Rating Hold: a genuinely improving franchise re-rating with visible growth, but priced around fair value, with a defensible entry only in the low-to-mid US$20s, below the conservative fair value of US$28.

Chow Tai Fook Jewellery Group: A Scale Leader in Transition, Priced Around Fair Value

Chow Tai Fook is the scale leader in Greater China branded jewellery, with a mostly franchised mainland network and a profit mix tilting toward higher-margin fixed-price gold products. FY2026 revenue rose 5.3% to HK$94.4 billion while operating profit jumped 27.8% to HK$18.85 billion on richer mix and store rationalisation, yet at HK$11.83 the shares sit around the base-case fair value of HK$12.2 with zero margin of safety and an unresolved debate over margin durability. Rating Hold: a cash-generative, scale-leading franchise re-rating on mix and discipline, but priced around fair value, with a defensible entry only below the conservative fair value of HK$9.8.

Nabtesco: A Scarce Robot-Reducer Franchise Carrying a Growth Premium on a Still-Cyclical Base

Nabtesco is a diversified Japanese precision-machinery group whose profit engine is industrial-robot RV reducers, where it holds about 60% of the global market for medium- to large-joint reducers, backed by transport, aircraft, marine, and door-system businesses. FY2025 continuing-operations sales rose 9.8% and operating income 60.3%, yet at JPY 5,707 the stock trades near record highs at roughly 36x FY2026 EPS and 43x FY2025 EPS, pricing in both the cyclical recovery and a large slice of still-unproven humanoid optionality. Rating Watch: a genuine franchise on a capital-heavy cyclical base, with no margin of safety until the mid-3,000s.

Shenzhen Zhaowei: A Real Precision Micro-Drive Business Undergoing a Thematic Robot Re-Rating

Zhaowei is a 25-year-old precision micro-drive systems supplier whose 2025 revenue was RMB1.72 billion, with automotive the real engine at 64.5% of sales while the headline-grabbing embodied-robotics line was just 1.39%. The A-share trades at about 91.5x trailing earnings and the H-share implies a roughly 46.6% discount, so the market is pre-paying for a humanoid-supply-chain future that the filings have not yet delivered. Rating Hold: a credible micro-drive platform with real robot optionality, but the A-share still prices too much of that optionality in advance; the ideal buy zone is CN¥44-61.

Akeso, Inc.: A Commercial-Stage Antibody Innovator Still Priced on Ivonescimab's Global Option Value

Akeso is a commercial-stage Chinese antibody innovator with seven marketed products and record 2025 commercial sales of RMB3.03 billion, anchored by cadonilimab and ivonescimab. Yet the stock trades as a referendum on one molecule: whether ivonescimab's strong China data (a HARMONi-6 overall-survival win, HR 0.66) can survive global regulators, while 2025 operating cash flow stayed negative at RMB947.6 million and the shares fetch about 22x trailing sales. Rating Hold: rare science and a real China franchise, but the price still pre-pays too much of ivonescimab's ex-China upside; the ideal buy zone is HK$58-64.

XtalPi Holdings: An AI-for-Science Platform Climbing from Fee-for-Service Work to Milestone Economics, Still Priced Ahead of Proof

XtalPi is a founder-led AI-for-science platform built by MIT-trained physicists, selling drug-discovery and R&D-automation solutions as it tries to climb from fee-for-service work toward milestone-and-royalty economics. 2025 revenue jumped 201.2% to RMB802.6 million as drug-discovery solutions rose to RMB537.9 million from RMB103.7 million, but one customer was over 45% of sales, reported profit leaned on RMB514.0 million of fair-value gains, and operating cash flow stayed negative at RMB-165.4 million. Rating Hold: serious science with blue-chip partners (DoveTree, Lilly, Pfizer) and a large cash cushion, yet the price still pays for cleaner, broader earnings than the platform has delivered; the ideal buy zone is HK$3.8-4.1.

Asymchem Laboratories: A Proven Small-Molecule CDMO in Transition to New Modalities, Already Priced for Success

Asymchem is a founder-led Chinese CDMO anchored in commercial small-molecule process chemistry, with emerging peptide, oligonucleotide and biologics work now about 30% of revenue. 2025 revenue rose 14.9% to RMB 6.67bn with adjusted net profit of RMB 1.25bn, order backlog reached US$1.385bn (+31.65%), and Q1 2026 emerging-business revenue jumped 74.1% — yet the A-share trades near 40x trailing earnings (about a 2.4% owner-earnings yield), while founder-concentrated governance and the BIOSECURE policy overhang cap the multiple. Rating Hold: a high-quality chemistry franchise whose new-modality transition is real, but the current price already pays for most of the 2026 recovery; the ideal buy zone is CNY 68-70.

Energy Transfer LP: A Discounted Midstream Cash Cow Turning Its Asset Empire Into Disciplined Gas-Led Growth

Energy Transfer is a roughly $66bn K-1 master limited partnership that owns about 140,000 miles of integrated U.S. gas, NGL, crude and export infrastructure across 44 states, throwing off $8.20bn of distributable cash flow to partners against a $4.56bn payout, or about 1.8x coverage. Its 2026 EBITDA guidance has been raised twice to $18.2bn-$18.6bn as a gas-and-NGL project backlog converts to cash, yet a 2020 distribution cut, MLP governance frictions and heavy reinvestment keep the units on a roughly 7.1% yield and a persistent structure discount. Rating Hold: integrated bottlenecks support a safe payout and organic reacceleration, but the discount closes only partly until disciplined execution is proven through repetition rather than another deal.

Graco Inc.: A Premium Fluid-Handling Compounder Priced for a Recovery Not Yet Visible

Graco is a century-old, distributor-led fluid-handling equipment maker with premium-industrial economics — high-20s operating margins, ~23% ROIC, and ~40% of revenue from parts and accessories. But organic sales fell 6% in Q1 2026 and reported growth now leans on bolt-on M&A (Valco Melton at ~14x EBITDA), while the stock trades near 24.8x earnings with no margin of safety. Rating Hold: a good company at an ordinary price, already priced for a cleaner recovery than the evidence yet shows.

MKS Inc.: A Hybrid Process-Control Platform Priced for a Near-Best-Case AI Cycle

MKS is a picks-and-shovels supplier of vacuum, photonics, and materials and chemistry technologies to semiconductor and advanced-packaging manufacturing, reshaped by the 2022 Atotech deal into a hybrid that is part cyclical subsystem vendor and part recurring-chemistry platform. Full-year 2025 revenue reached US$3.93 billion with semiconductor and electronics-and-packaging both growing double digits, and the February 2026 refinancing eased the post-Atotech debt strain, yet at about US$406 the stock trades near 34x trailing EBITDA and 52x non-GAAP earnings. Rating Avoid: a genuinely better business than two years ago, but the price already discounts a near-best-case AI and packaging cycle, with a margin of safety only opening below roughly US$180.

Renesas: A Cyclical Embedded Compounder Priced for a Transition Still Unproven

Renesas is a cyclical embedded-semiconductor compounder centered on automotive MCUs, with analog, power, and connectivity layers and a new system-design software push after Altium. Q1 2026 non-GAAP revenue rose 20.6% to JPY 372.3 billion at a 59.2% gross margin, and 2025 free cash flow reached JPY 328.2 billion, yet IFRS profit swung to a loss on Wolfspeed-related impairments. Rating Hold: a real franchise with better cash than the headlines, but at JPY 4,734 the price already discounts much of the recovery, with a wider margin of safety only opening in the JPY 3,500-3,800 range.

Sartorius AG: A Quality Bioprocess Recovery Already in the Price

Sartorius AG is a German life-science tools group whose value is dominated by its majority-owned bioprocess franchise, Sartorius Stedim Biotech, with the liquid quotation being the non-voting preference share SRT3. After a pandemic boom and a destocking bust, 2025 sales recovered 7.6% to about EUR 3.54 billion, underlying EBITDA margin returned to 29.7%, and leverage fell from 3.96x to 3.55x, yet roughly EUR 3.74 billion of net debt and a still-premium 18x trailing EBITDA leave little cushion. Rating Hold: the franchise and the recovery are both real, but the market already sees the normalization and the current EUR 217.10 price sits above the report's ideal buy zone.

TAL Education Group: A Cash-Rich Rebuild with a Hardware Question

TAL is a cash-rich China education company rebuilt around legal enrichment classes, learning devices, and content after the 2021 tutoring crackdown. FY2026 revenue reached about US$3.01 billion (up 33.7%) and net cash is roughly US$3.24 billion, but reported earnings are flattered by about US$347 million of non-operating gains and VIEs supplied 78.6% of revenue. Rating Hold: the rebuild is real, yet normalized earnings, device durability, and China-structure risk leave the stock fairly priced rather than compelling.

Viasat 卫星通信深度研究

Viasat 是面向航空、海事、政府与国防的全球卫星通信运营商，收入分通信服务（约 33.0 亿美元）与国防先进技术 DAT（约 13.41 亿美元）两大块。FY2026 营收约 46.4 亿美元、自由现金流转正、净债务降到约 48 亿美元、杠杆约 3.1 倍，但 Starlink 已在航空抢下 7000 架以上飞机合同。研报评级持有：国防与航空在改善现金流，但 LEO 竞争与债务让现价仅适合持有。

网易 NetEase 深度研究

网易是中国最依赖自研游戏的互联网公司，2025 年约 82% 收入来自游戏。当前看点是 243 亿美元净现金撑起的成熟现金流，与《Where Winds Meet》《Marvel Rivals》能否把海外第二曲线做实之间的拉锯；静态市盈率约 16.5 倍并未给出折价。研报评级持有：高质量游戏现金流稳健，但当前价位对海外新作兑现已部分预支。

10x Genomics 深度研究

10x Genomics 是单细胞与空间组学平台商，靠仪器装机带动高毛利耗材复购，耗材长期占收入约 84%–86%。Chromium 增速放缓后，增长寄望 2026 年 4 月发布的 Atera 接棒，但公司仍亏损、约四到五成收入依赖学术与政府经费。研报评级持有：现价 28.84 美元对应前瞻 EV/Sales 约 5.1 倍，合理但没有安全边际。

阿斯利康 AstraZeneca 深度研究

阿斯利康是以肿瘤与罕见病为核心、靠研发与全球商业化变现的创新药巨头。2025 年收入 587.39 亿美元，增长重心向肿瘤（同比 +20%）与罕见病（+19%）集中、对冲 CVRM 老药承压，多平台结构比单引擎同业更均衡。研报评级持有：现价 178.75 美元对保守内在价值仍有溢价、安全边际不明显，高质量但已进入兑现压力期。

汇川技术 Inovance 深度研究

汇川技术是中国工控平台龙头，靠工业自动化与新能源汽车电驱双主线赚取设备与系统利润。2025 年自动化业务体量与汽车接近却贡献约七成毛利，整体毛利率从 31.7% 降到 28.1%，增长质量正被重写。研报评级持有：现价 67.16 元已接近中性情景低端、安全边际为零，是好公司但价格不再慷慨。

Airbus SE 深度研究

空中客车是欧洲民机双寡头之一，靠 A320neo/A350 民机交付、全生命周期服务与防务航天三组业务变现。2025 年录得 734 亿欧元收入、45.7 亿欧元客户融资前自由现金流、净现金 122 亿欧元，但 2026 年一季度交付偏低令现金流转负，全年 870 架目标要求下半年月均交付约 87 架；当前股价 179.28 欧元对应 forward PE 约 25 倍，并不便宜。研报评级持有：高质量成熟现金牛，买的是执行修复，当前安全边际为零、值得等更好买点。

联华电子 UMC 深度研究

联华电子是台湾晶圆代工双雄之一，主攻 22/28nm 成熟与特殊制程。2026 年一季营收 NT$610.4 亿、毛利率 29.2%，但 EPS 同比翻倍主要靠非营业收益放大、现价对应市净率 3.87 倍与调整后约 31 倍市盈率并不便宜。研报评级观察：周期温和修复属实，但当前价已把乐观情景大半计入。

京元电子 KYEC 深度研究

京元电子是全球最大的纯第三方半导体测试厂，AI 芯片测试是核心增量。2026 年一季营收首破百亿新台币、毛利率连五季升到 39.7%，但 2026 年资本开支上调到 500 亿元远超去年营收、现价 NT$282 对应约 37 倍市盈率、安全边际接近为零。研报评级持有：AI 测试需求真实，但高资本强度与峰值估值都需消化。

金山办公 Kingsoft Office 深度研究

金山办公是中国办公软件龙头，WPS 个人订阅、机构授权与协作 SaaS 三块支撑收入。2025 年收入 59.29 亿元，WPS AI 月活冲到 8013 万、年付费个人用户近 4900 万，但 2026 年一季净利暴增主因投资收益、经营口径市盈率仍约 55 倍。研报评级持有：AI 进入转化层是真，但表观利润失真、估值仍贵。

浪潮信息 Inspur 深度研究

浪潮信息是中国 AI 服务器与算力基础设施整机龙头，服务器收入占比超九成。2025 年营收 1647.82 亿元、同比增 43.25%，但服务器毛利率从 6.76% 降到 4.52%、2026 年一季经营现金流又转负 77.72 亿元。研报评级持有：故事更大了，利润与现金兑现依旧很慢，规模没换来定价权。

国巨 Yageo 深度研究

国巨是靠并购整合做大的高端被动元件与传感器平台，产品涵盖 MLCC、钽电容与芯片电阻。2026 年一季毛利率升到 38.1%、归母净利 80.01 亿元同比增 44.7%，但现价 NT$855 对应追踪市盈率约 67 倍、安全边际接近没有。研报评级持有：平台化与 AI 高端料逻辑成立，但当前价已基本反映中性偏乐观情景。

优必选 UBTech 深度研究

优必选是中国「人形机器人第一股」，主营从教育服务机器人转向工业人形机器人本体。2025 年人形机器人收入 8.21 亿元、占比 41.1%、销量 1079 台暴增 2203.7%，首次成第一大收入来源，但全年净亏 7.90 亿元、23.4 倍市销率。研报评级持有：商业化已过零到一，但价格透支较多 2027 年扩张预期。

英维克 Envicool 深度研究

英维克是中国本土全链条液冷系统供应商，做数据中心与储能温控、液冷部件到机房级方案。2025 年营收 60.68 亿元、同比增 32.23%，但归母净利仅增 15.30%、经营现金流 1.57 亿元远弱于 5.22 亿元净利，静态市盈率约 161 倍。研报评级观察：液冷景气确定，但现金流与估值都没给出安全边际。

铠侠控股深度研究

铠侠控股是从东芝分拆、与 SanDisk 深度合营的 NAND/SSD 存储原厂，也是日本市场稀缺的纯存储兼 AI 推理标的。FY2026 营收冲到 2.34 万亿日元、利润爆发，但当日市值约 44.36 万亿日元对应 TTM 市盈率约 79 倍，且利润高点主要靠 ASP 上冲而非销量，现价已高于乐观估值上沿。研报评级避免：公司修复是真的，但股价把 AI 与去周期化预期透支得过早。

智邦科技 Accton 深度研究

智邦科技是面向云厂商与 AI 数据中心的白牌以太网交换机 ODM，开放网络与 OCP 资历深厚。2025 年营收跳增至 2483 亿元、2026 年一季营收同比再增 64%、营业利润率升至 14.3%，但当前 TTM 市盈率约 44 倍、美洲收入占比 81%、一季库存单季暴增 67%，估值已大幅透支增长。研报评级持有：AI 网络基本面很强，但当前价格已反映高增速与再评级，安全边际为零。

乐动机器人深度研究

为服务机器人厂商供应视觉感知模组、兼营自有品牌割草机器人出海，2025 年收入约 7.48 亿元。2026 年 5 月刚登陆港交所，现价对应约 15.7 倍市销率、远高于感知同业的 5-6 倍，市场已提前计入两年后的兑现。研报评级观察：双轮业务有潜力，但现价安全边际为零，理想买入区 16-18 港元。

Tesla 深度研究

以电动车为现金流底座，叠加储能、充电网络与自动驾驶/机器人期权的平台型公司。2025 年储能收入增长 27% 成为第二增长曲线，但汽车收入下滑 10%、利润倚重政策红利，市场已按自动驾驶成功提前定价。研报评级持有：好公司，但 396.68 美元的现价透支了太多未验证的远期预期。

罗尔斯·罗伊斯(RR.LSE) 横纵研报

罗尔斯·罗伊斯是英国航空发动机、舰船动力、电力系统、核电（民用 SMR + 军用核潜艇推进）"四面兼具"的国宝级综合工业集团；2022 年股价跌至 70 便士濒临破产，2023 年初新 CEO Tufan Erginbilgiç 上任启动"燃烧的平台"激进重组，3 年内股价飙至 1260 便士涨 18 倍。当前营收 ~212 亿英镑、营业利润率 20%、EBITDA ~46 亿英镑；英国 GBN 已选定 RR SMR 设计为国家小型模块化反应堆首选方案。

nVent Electric (NVT) 横纵研报

nVent 是从 Pentair 2018 年分拆独立的电气基础设施供应商，主营数据中心 IT 机柜、液冷 CDU/RDHx、模块化数据中心建筑（Trachte）和中低压配电开关柜（Avail EPG），AI 数据中心是当前最强增长引擎；2025 年初以 17 亿美元剥离 Thermal Management 业务回收现金，随后以 ~16.6 亿美元连续收购 Trachte 与 Avail EPG，集中押注"数据中心铲子"，2024 财年营收约 33.5 亿美元、营业利润率 ~20%。

AeroVironment(AVAV) 横纵研报

美军巡飞弹(Switchblade)与小型无人机(Puma/Raven)主力供应商，踩在「无人机主导」这一代国防最强顺风上(FY2027 DAWG 预算请求 546 亿美元)；41 亿美元全股票并购 BlueHalo 后整合磕绊集中兑现——Q3 营收 miss、毛利率从 38% 压到 24%、1.51 亿美元太空商誉减值、砍全年指引、GAAP 转亏、证券集体诉讼。

BWX Technologies(BWXT) 横纵研报

美国海军核动力反应堆/堆芯/核燃料的事实唯一制造商，护城河近乎不可逾越，政府积压订单约 70 亿美元、需求受多年期国策(哥伦比亚/弗吉尼亚级潜艇)刚性支撑；同时手握核能复兴卖铲人期权(Project Pele 微堆、BWRX-300 反应堆压力容器、医用同位素)。

三星生物（Samsung Biologics，207940）横纵框架深度研究：刚剥离成纯 CDMO 的全球代工龙头，好生意撞上贵价格与未兑现的 BIOSECURE 红利

全球最大生物药 CDMO（合同开发与生产），2025 年 11 月把生物类似药子公司 Bioepis 分拆出去、转型纯 CDMO。产能全球第一（~78 万升）、营业利润率约 45%、营收增长 30%+、绑定全球前 20 大药企中 17 家、在手订单 $21.4B。

金力永磁（300748）横纵框架深度研究：全球稀土永磁龙头，业绩 V 反转撞上贵估值与机器人故事

A股稀土永磁绝对龙头，做高性能钕铁硼磁材，下游新能源车（约56%）/变频空调/风电/机器人。业绩 V 型反转（2024 归母 2.9 亿→2025 7.06 亿、+142%）主要靠镨钕涨价（氧化镨钕 2024 低谷 36 万→2026 春季高点约 76 万、基准日约 70 万元/吨）+EV 放量。

罗氏（Roche）横纵框架深度研究：熬过专利悬崖的诊断+制药巨头，公道价格撞上争议增长

全球体外诊断第一 + 顶级制药（肿瘤/神经/眼科），家族控股、瑞郎计价。熬过专利悬崖、新药已补满约 100 亿美元缺口、集团回到 +7% 恒汇增长，但强瑞郎吞掉报告增速（仅 +2% CHF）。约 16× 前瞻 PE、3% 股息（39 年贵族）、较 2022 高点低 27%，估值公道但增长有争议；减肥迟到是最大期权。评级持有，理想买点 ≤CHF 295。

Schrödinger(SDGR) 横纵研报

物理基础（FEP+ 金标准）的计算药物发现平台，全球前 20 大药企 19 家是软件客户，叠加自有/合作管线与可重复的股权变现（Nimbus/Morphic/Ajax 累计套现约 7 亿美元）。当前市值约 11 亿、净现金约 3 亿，距 2021 峰值 -86%。

SiTime(SITM) 横纵研报

全球唯一规模化的 MEMS 精密计时玩家，靠硅基振荡器物理替代石英晶振，MEMS 细分份额 80%+，AI 数据中心驱动 Q1'26 营收 +88%、FY26 指引 ≥80%。$32 亿收购瑞萨 timing 业务带来杠杆/摊薄/整合不确定。

三花智控（002050.SHE）横纵深度研究

全球制冷控制元件绝对龙头（四通阀约 55%、电子膨胀阀约 51% 全球第一）+ 新能源车热管理 Tier-1 + 人形机器人执行器期权。FY25 营收 310 亿、归母 40.6 亿（+31%）、毛利率 28.8%、ROE 15.8%、近净现金，主业优质。

Cognex 横纵框架深度研究：机器视觉的「眼睛」，好生意撞上贵价格

全球第二的机器视觉龙头，68% 毛利、24% FCF 利润率、零负债，Q1 营收重新加速 +24%；但 76× TTM PE / 44× 前瞻 PE 处历史估值带顶部，对每家可比公司都溢价（多数 2-3 倍），半年股价翻倍后安全边际为零。好生意，贵价格，评级观察，真正买点在 $40-49。

奇鋐科技 横纵分析法深度研究

全球最大系统散热厂、英伟达 AI 服务器液冷核心供应商，FY2025 营收破千亿（YoY +95%）、EPS 49.17 元，Q1'26 EPS 20.17 元创高、确属真加速。

Redwire 长期所有者视角研究：好赛道，未证明的好公司

太空基础设施+国防无人系统平台，需求真实但商业质量未证明，Owner Earnings 仍负、稀释与内控风险高；当前 18.62 美元已贴乐观估值上沿，无安全边际。

工业富联横纵研究：AI 服务器代工份额第一，业绩真加速但生意薄、估值贵

英伟达 GB200/GB300 NVL72 机柜级 AI 服务器全球最大组装商（份额约 45-48%），业绩真加速（FY25 营收+48%/净利+52%、Q1'26 净利+102%）；但本质低毛利代工（毛利仅 6.94%、议价权弱）。

Bruker 横纵研究：科学仪器隐形冠军，但有机增长退潮、估值已透支复苏

全球高端科学分析仪器隐形冠军（NMR 近寡头垄断），但有机增长连续转负（FY25 -3.7%/Q1'26 -4.4%）、报告增长全靠并购+汇率、GAAP 转亏，盈利复苏全押成本削减；月内暴涨约 70% 后现价 $59.97 高于卖方均值目标 16%、远期 PE ~27-28× 处同业上沿。评级观察，安全边际待有机拐点或回到约 $48。

Cameco 横纵研究：西方铀业龙头，但价格已替核能复兴预付太多

全球最大公开上市铀生产商、西方核燃料循环支柱，踩中 AI→核能复兴主线；但 PE 约 107×、EV/EBITDA 约 50–78× 处历史顶部、远高于第三方公允价 $47–87，铀价剧烈周期且已见顶回落。评级观察，安全边际待股价回到约 $80。

Planet Labs（PL）长期所有者视角研究

好故事、还不错的公司、很差的价格。FY2026 营收 3.077 亿美元、增速 26%，但 43 倍市销率已透支十年近乎完美执行；正自由现金流主要靠递延收入推动，真实 owner earnings 仍未证明，安全边际不足。

Voyager Technologies 长期所有者视角研究

国防太空承包商 + Starlab 商业空间站期权，仍深度亏损、owner earnings 为负。评级观察：现价 44.96 美元已接近乐观情景下限，无安全边际，理想买入 18–25 美元。

BlackSky Technology 长期所有者视角研究

方向正确但尚未完成现金流验证的航天情报成长股。当前约 37.48 美元已接近乐观情景上沿，长期负所有者收益、客户集中度 89%、持续稀释，安全边际不成立。

Karman Holdings 长期所有者视角研究

优质军工航天赛道、客户嵌入深，但 2025 年经营现金流转负、杠杆高企、有形净值为负，现价 51.84 美元远高于合理内在价值 13-20 美元，安全边际明确没有——好公司雏形、坏价格。

Firefly Aerospace 长期所有者视角研究

技术强、故事好，但好生意/宽护城河/可分配现金流/安全边际四件事都未证明；自由现金流与所有者收益仍为负，客户集中度超 86%，当前价无安全边际。评级避免。

Federal Realty Investment Trust 长期企业所有者视角深度研究

好资产，价格不便宜。FRT 是美国开放式零售 REIT，资产质量与分红纪律俱佳，但现价约 15.9 倍前瞻 FFO、股息率 3.8% 低于美债，安全边际不足；合理买入 85–100 美元。

Revvity 价值投资深度研究

评级观察。业务可理解、现金流尚可，但护城河和资本回报率不够强，GAAP ROIC 低个位数，商誉 66 亿美元。中性内在价值 65–75 美元，当前约 101 美元已近乐观情景低端，安全边际不足。理想买入区间 50–65 美元。

Tyler Technologies 深度价值投资研究

美国地方政府垂直软件龙头，做法院、公共安全、税务、ERP 与支付平台，经常性收入占比 87%、客户留存 98%、转换成本极高。生意质量过关但当前约 313 美元股价已计入高质量软件溢价，安全边际不足，给观察评级，理想买入区间 220-260 美元。

Stanley Black & Decker 深度价值投资研究

DeWalt/Craftsman 电动工具与户外产品 + 工程紧固件的老牌工业公司，2022 年资本配置翻车后正在修复，毛利率与现金流回升但 ROIC 仍低；当前约 79 美元处于中性内在价值附近，安全边际不明显，给观察评级，理想买入区间 55-70 美元。

Hasbro 深度价值投资研究

玩具 + 桌游卡牌(Magic/D&D) + IP 授权混合体，Wizards 分部极优而消费品业务平庸且留有 eOne 减值后遗症。当前约 86 美元处在中性偏下，安全边际不足，给观察评级，理想买入区间 55-65 美元。

Huntington Ingalls Industries 深度价值投资研究

美国军用造船龙头，唯一能建造换料退役核动力航母、仅有两家核潜艇建造商之一，客户几乎全是美国政府。结构性壁垒极深但 ROIC 仅中个位数、现金流随合同节奏大幅波动，当前约 308 美元已为稀缺性付足价格，安全边际不明显，给观察评级，理想买入区间 220-260 美元。

Everest Group 深度价值投资研究

全球性 P&C 再保险与商业保险承保平台，靠评级、资本和经纪关系组合护城河赚承保利润加浮存金收益。生意能理解但盈利受灾害、长尾准备金和费率周期摆布；当前约 324 美元对应 0.84 倍账面价值、6.6 倍 TTM PE，便宜但便宜有因，安全边际不够厚，给观察评级，理想买入区间 260-290 美元。

Trimble 深度价值投资研究

工业软件+定位/现场系统+物流平台公司，正从硬件商转向订阅与经常性收入，护城河多重中等、现金流质量改善但治理有瑕疵。当前约 56 美元更接近合理而非便宜，安全边际不足，给观察评级，理想买入区间 38-45 美元。

News Corp Class A 深度价值投资研究

News Corp 无投票权 A 类股，与有投票权的 NWS（B 类）同公司不同股份类别。公司是 Dow Jones、REA/Move 数字房产、HarperCollins 与新闻媒体拼成的混合信息服务控股体，护城河分部不均、合并 ROE 仅中单位数、Murdoch 双层股权带来治理折价。当前约 26.10 美元落在合理价值区间内、自由现金流收益率低于美债，安全边际不足，给观察评级，理想买入区间 20-23 美元。

Solventum 深度价值投资研究

3M 分拆的医疗科技公司，主营器械耗材、牙科材料与医院软件，需求刚需但护城河中等。当前约 75 美元不算贵也无明显安全边际，自由现金流尚未证明修复、仍依赖 3M 供应链，给观察评级，理想买入区间 55-65 美元。

TKO Group 深度价值投资研究

以 UFC、WWE 为核心的稀缺体育 IP 与版权分销商，品牌强、版权可签多年长约、资本强度低，生意质量优于多数文娱公司。但当前约 205 美元股价对应去年自由现金流约 34.5 倍，安全边际不足，且高估值区债务回购侵蚀复利质量，给观察评级，理想买入区间 90-110 美元。

UDR 深度价值投资研究

美国多户住宅（公寓）REIT，资产分散、投资级信用、运营执行稳健，但护城河属区位+规模+低融资成本的组合型而非品牌垄断。生意质量过关，当前约 36.91 美元股价落在合理内在价值区间偏下、安全边际不充分，给观察评级，理想买入区间 30-34 美元。

Masco 深度价值投资研究

北美家装建材品牌组合公司，靠 Behr 涂料、Delta 水暖等品牌吃住宅维修翻新刚需，现金流扎实、回购纪律好。生意质量过关但增长偏慢、对家得宝渠道依赖高，当前约 70 美元股价已接近合理价值，安全边际不足，给观察评级，理想买入区间 55-60 美元。

DaVita 深度价值投资研究

美国终末期肾病透析中心连锁龙头，需求刚性、现金流强、回购执行力出色，但几乎全部利润依赖高价商业保险，且账面负权益、净杠杆 3 倍以上。当前约 194 美元处于保守与中性估值之间，安全边际不够厚，给观察评级，理想买入区间 150-170 美元。

Genuine Parts 深度价值投资研究

北美汽车后市场（NAPA）与工业 MRO（Motion）分销商，需求稳、护城河中等，但靠并购扩张、现金流弱于调整后利润。当前约 99 美元落在合理价值区间中部，安全边际不明显，给观察评级，理想买入区间 70-85 美元。

McCormick 深度价值投资研究

全球香辛料与调味品龙头，品牌渠道强、现金流稳，但已置身与 Unilever Foods 的大型反向并购事件中，杠杆抬升、增长靠提价。前瞻 PE 约 15 倍、当前约 47 美元仅压在合理价值下沿，安全边际不足，给观察评级，理想买入区间 40-43 美元。

Jacobs Solutions 深度价值投资研究

全球第一的工程设计与咨询平台，持续向高附加值咨询转型、订单能见度强，但护城河中等、ROIC 不到 10% 低于同行，估值横向偏贵。约 120 美元现价落在合理价值区间上沿，安全边际不充分，给观察评级，理想买入区间 75–90 美元。

Healthpeak Properties 深度价值投资研究

美国医疗地产 REIT，靠门诊医疗楼与生命科学实验室物业收租、再开发，现金流真实、负债表稳健、估值不贵，但护城河不宽、资本密集、实验室仍承压。生意可理解、资产有锚，但当前约 19.15 美元对应约 11 倍 owner earnings，相对合理内在价值折价不厚，安全边际不明显，给观察评级，理想买入区间 16.5-18 美元。

Zimmer Biomet 深度价值投资研究

全球骨科植入物厂商，主营膝髋关节、运动医学/创伤/四肢产品及 ROSA 机器人与数字化平台，需求受老龄化与骨关节炎长期支撑、现金流真实。生意质量过关但增长质量与护城河不及 Stryker，当前约 82 美元估值不贵却只对中性价值有折价，安全边际不足，给观察评级，理想买入区间 65-75 美元。

Regency Centers 深度价值投资研究

美国杂货店锚定的开放式社区购物中心 REIT，抗电商、信用 A-/A3、同店增长稳健，生意质量上乘。但当前约 77 美元已贴合理价值区间上沿，约 16.8 倍前瞻经营收益，安全边际不足，给观察评级，理想买入区间 58-68 美元。

Weyerhaeuser 深度价值投资研究

北美最大林地与木制品平台之一，控制约 1,040 万英亩美国林地，资产优质但 Wood Products 收入主体商品化、强周期、弱定价权。生意可理解，现金流真实但波动极大，当前约 24.51 美元股价落在合理内在价值区间、对保守区间反而溢价，安全边际不明显，给观察评级，理想买入区间 17-20 美元。

Lululemon Athletica 深度价值投资研究

高端运动服饰品牌，直营全渠道驱动高毛利、高 ROIC、净现金；生意质量过关但北美增长出现裂缝、品牌热度承压、管理层更替，当前约 131 美元安全边际不足，给观察评级，理想买入 105-120 美元。

Tractor Supply 深度价值投资研究

美国最大的乡村生活方式零售连锁，靠饲料、宠物、五金等高频刚需驱动需求，运营型护城河稳固、资本回报优秀。生意质量过关，但当前约 31.53 美元股价更接近合理价而非明显打折，安全边际不够厚，给观察评级，理想买入区间 25-29 美元。

PTC 深度价值投资研究

工业软件厂商，卖给制造业客户的 CAD/PLM/ALM/SLM 产品数据主线工具，收入约 95% 经常性、转换成本高、现金转换强。生意质量过关但当前约 138.73 美元股价对应的保守所有者收益收益率仅约 4%，相对美债不宽裕，安全边际不足，给观察评级，理想买入区间 95-115 美元。

NVR 深度价值投资研究

美国轻土地模式住宅建造商，以 Ryan Homes 等区域品牌建房卖房并配套自有客户按揭，ROIC 显著高于同行、资本配置纪律强。生意质量过关但行业强周期、对利率敏感，当前约 6105 美元股价已计入溢价、安全边际不足，给观察评级，理想买入区间 4500-5300 美元。

Leidos Holdings 深度价值投资研究

美国最大政府科技与工程承包商，约 87% 收入来自联邦政府，需求稳定、现金流真实但护城河仅中等、定价权受竞标约束。当前约 127.81 美元处合理区间下沿，不贵但安全边际不明显，给观察评级，理想买入区间 95–110 美元。

Textron 深度价值投资研究

以航空与国防为主、夹带工业的多业务集团，靠 Cessna/Beechcraft 公务机与 Bell 直升机赚钱，品牌与认证壁垒真实但护城河各板块强弱不均。现价约 91.76 美元约合 16-17 倍保守 Owner Earnings，比同行便宜却安全边际不足，给观察评级，理想买入区间 72-82 美元。

Gen Digital 深度价值投资研究

消费者数字安全订阅平台，Norton/Avast/LifeLock 多品牌加 MoneyLion 金融健康，轻资产强现金流，但行业无实质进入壁垒、平台方免费捆绑、负债约 82 亿美元，护城河中等偏弱。当前约 25.79 美元基于 FCF 不贵但安全边际不明显，给观察评级，理想买入区间 20-23 美元。

Mid-America Apartment Communities 深度价值投资研究

美国 Sun Belt 多户住宅 REIT，自持自营公寓、收入分散且高度重复，资产与资产负债表稳健但护城河不深。当前约 129 美元股价对应保守所有者收益约 21—22 倍、收益率 4.5%—4.8%，与 10 年期美债接近，安全边际不充分，给观察评级，理想买入区间 95-110 美元。

Generac 深度价值投资研究

北美电力韧性设备龙头，主营家用/商工备用发电机与储能能源管理，护城河中等、需求带周期与天气驱动。生意可理解，但当前约 278 美元股价已把修复与成长提前计入，安全边际不足，给观察评级，理想买入区间 95-130 美元。

IDEX Corporation 深度价值投资研究

由数十个高毛利、任务关键型工业与生命科学零部件业务拼成的应用解决方案平台，客户极分散、现金流扎实、护城河碎片化但真实。生意质量过关，但当前约 211 美元股价对应 FCF 收益率低于 10 年期美债，安全边际不足，给观察评级，理想买入区间 105-130 美元。

International Paper 深度价值投资研究

全球纤维基包装企业，做箱板纸与瓦楞箱、偏周期重资产，护城河靠区域规模与执行而非品牌。生意能懂但质量一般，2025 年大并购后快速减值约 25 亿美元、每股被股权稀释，当前约 33.47 美元落在合理价值下沿、安全边际不足，给观察评级，理想买入区间 24-29 美元。

Nordson 深度价值投资研究

精密流体管理与点胶/测试检测/医疗部件的多利基工业平台，毛利率长期 55%、现金流质量高、护城河靠流程嵌入与切换成本。生意优秀但当前约 287 美元已接近合理价值，安全边际不充分，给观察评级，理想买入区间 220-250 美元。

Host Hotels & Resorts 深度价值投资研究

美国公开市场规模最大、唯一投资级的高端酒店 REIT，资产质量与资本配置过关但行业周期性强、资本开支重、护城河不宽。当前约 22.98 美元股价落在合理内在价值区间中段，安全边际不明显，给观察评级，理想买入区间 18-20 美元。

Kimco Realty 深度价值投资研究

美国最大的开放式、杂货锚定社区购物中心 REIT，租金现金流稳、负债表强、护城河中等偏强。生意可理解、质量过关，但当前约 24 美元股价对应约 13 倍前瞻 FFO，相对保守内在价值反有溢价，安全边际不足，给观察评级，理想买入区间 18-21 美元。

Invitation Homes 深度价值投资研究

美国单户独栋住宅租赁 REIT，全资加管理超 10.9 万套，规模、运营与融资优势真实，但利率与成本敏感、增长中速。当前约 29 美元股价对应 17.8 倍 AFFO，大致公允偏贵，安全边际不足，给观察评级，理想买入区间 20-24 美元。